When a company such as CRME conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the CRME split history from start to finish, an original position size of 1000 shares would have turned into 200 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into CRME shares, starting with a $10,000 purchase of CRME, presented on a split-history-adjusted basis factoring in the complete CRME split history.

About CRME

Correvio Pharma is engaged in the discovery, development and commercialization of drugs to treat or prevent cardiovascular diseases. Co.'s product, BRINAVESS™, is approved for marketing in the European Union, Iceland and Norway for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. Co.'s clinical programs are also focused on the treatment of atrial fibrillation, an arrhythmia (or abnormal rhythm) of the upper chambers of the heart. Co. also has a few pre-clinical projects directed at various therapeutic indications that focus on modulating cellular proteins (ion channels) for cardiac diseases. According to our CRME split history records, CRME has had 1 split.

CRME Split History | www.SplitHistory.com | Copyright © 2013 - 2024, All Rights Reserved